Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study

Lancet

Volumn 357, Issue 9256, 2001, Pages 592-598

  Martinez, Esteban ^a   Mocroft, Amanda ^b   García Viejo, Miguel A ^a   Pérez Cuevas, José B ^a   Blanco, José L ^a   Mallolas, José ^a   Bianchi, Luis ^a   Conget, Ignacio ^a   Blanch, Jordi ^a   Phillips, Andrew ^b   Gatell, José M ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

AGE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME;

EID: 0035941778     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04056-3     Document Type: Article

References (34)

1. Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: The lipodystrophy syndrome
2. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
3. Visceral abdominal-fat accumulation associated with use of indinavir
4. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
5. Sonographic assessment of regional fat in HIV-1-infected people
6. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
7. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
8. Impact of switching from Human Immunodeficiency Virus type 1 protease inhibitors to efavirenz in successfully treated adult with lipodystrophy
9. Redistribution of body fat in HIV-infected women unergoing combined antiretroviral therapy
10. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
11. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
12. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
13. Incidence of fat tissue abnormalities in protease inhibitor-naive patients treated with NRTI combinations
14. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
15. Syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance due to HIV protease inhibitors
16. Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Society-USA panel
17. Changes in use of antiretroviral therapy in regions of Europe over time
18. Description of lipodystrophy in the HIV Outpatient Study (HOPS)
19. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
20. Prevalence of lipodystrophy and relation with clinical, anthropometric data and treatment, Aquitaine Cohort, 1999
21. Lipodystrophic syndromes in a cohort of HIV-1-infected patients receiving HAART with a protease inhibitor
22. Studies of body composition and fat distribution in HIV-infected and control subjects
23. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy
24. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women
25. Considerations in the development of a case definition for HIV/HAART-associated lipodystrophy syndrome
26. The SALSA (self-ascertained lipodystrophy syndrome assessment) cohort abnormalities in cases compared to controls
27. Abnormalities in HIV-associated lipodystrophy syndrome that vary by weight status
28. Total body potassium in aging humans: A longitudinal study
29. Studies in the distribution of body fat: Effects of the age, sex and obesity
30. Body fat distribution in healthy young and older men
31. Fat distribution and metabolic changes in patients with HIV infection
32. The effect of protease inhibitors on weight and body composition in HIV-infected patients
33. Effect of indinavir on HIV-related wasting
34. Beneficial effects of protease inhibitors on body composition and energy expenditure: A comparison between HIV-infected and AIDS patients